Mefenamic Acid + Paracetamol Suspension

Mefenamic Acid + Paracetamol Suspension belongs to the Suspensions category within the Analgesics & Pain Relief, Anti-Inflammatory, and Anti-Pyretic therapeutic segments — three of the highest-prescription-volume categories in Indian pharmaceutical practice.

The clinical logic of this two-molecule combination is straightforward and powerful for prescribers:

• Mefenamic Acid 100 mg — a non-steroidal anti-inflammatory drug (NSAID) that inhibits COX enzymes, reducing prostaglandin-mediated pain, inflammation, and fever. It is particularly effective for musculoskeletal pain, period pain, and dental pain.
• Paracetamol 250 mg — the gold-standard analgesic and antipyretic, providing central pain relief and fever reduction with an excellent safety profile at therapeutic doses.

For pharmaceutical marketing companies, this product is a seasonally robust SKU with repeat prescription cycles driven by the inevitable return of pain and fever conditions. Saar Biotech manufactures it from our manufacturing facility in Baddi with validated two-API suspension quality control and complete 60ml and 100ml packaging options.

At Saar Biotech, we manufacture Mefenamic Acid + Paracetamol Suspension using a controlled oral suspension manufacturing process that ensures dose uniformity, paediatric flavour acceptance, and packaging reliability for the highly competitive analgesic segment.

• Two-API Suspension Uniformity: Mefenamic Acid is a suspended solid that requires careful formulation to prevent sedimentation and inconsistent dosing — a critical failure mode for pain relief products. Our suspending agent system ensures rapid, uniform re-dispersion after shaking, so every 5ml dose delivers a consistent and predictable active load.

• Taste Masking: Analgesic suspensions must taste acceptable to patients who already feel unwell. We develop mango-flavoured suspension bases that mask the residual bitterness of Mefenamic Acid and Paracetamol — ensuring patients accept each dose without resistance, which is a genuine commercial differentiator.

• pH and Stability Management: Both Mefenamic Acid and Paracetamol must remain chemically stable for 24 months under tropical storage conditions. Our formulation team selects preservatives, pH buffers, and suspending agents that protect both actives from chemical degradation — ensuring the product on the pharmacy shelf retains its full label-declared potency.

• 60ml and 100ml Pack Coverage: From dark amber bottles to drip-off embossed cartons, metallic labels, and company-logo printed caps — Saar Biotech’s packaging options help analgesic brands stand out at pharmacy level.

Mefenamic Acid + Paracetamol Suspension is manufactured and supplied by Saar Biotech for the following established clinical indications:

• Pain & Inflammation: Mefenamic Acid’s NSAID action reduces pain and inflammation in musculoskeletal conditions, osteoarthritis, rheumatoid arthritis, and soft tissue injuries.

• Fever & Body Ache: Paracetamol’s antipyretic action rapidly normalises elevated body temperature driven by viral infections, influenza, and other febrile conditions — simultaneously relieving associated headache and body ache.

• Period Pain (Dysmenorrhoea): Mefenamic Acid is particularly effective for menstrual cramps due to its direct action on uterine prostaglandin synthesis.

• Dental Pain & Toothache: The combination addresses dental pain effectively, making it a common prescription in dental practice.

Schedule H — Must be dispensed on a valid medical prescription. Prolonged use should be avoided without physician supervision.

Dual-Component Clinical Mechanism

Mefenamic Acid inhibits cyclooxygenase (COX) enzymes — both COX-1 and COX-2 — preventing the conversion of arachidonic acid to prostaglandins and thromboxanes. This results in reduced inflammation, pain, and fever. Its NSAID properties make it particularly effective for inflammatory pain conditions.

Paracetamol acts primarily as a centrally-mediated analgesic and antipyretic. It inhibits COX-2 and COX-3 enzymes in the hypothalamus, reducing prostaglandin synthesis in the thermoregulatory centre. This hypothalamic action facilitates vasodilation and sweating to reduce fever, while its analgesic effects are mediated through descending serotonergic pathways.

Manufacturing Integrity

• Two-API Suspension Uniformity: Each of the two active ingredients must be uniformly distributed in the suspension vehicle. Saar Biotech’s high-shear mixing and validated fill procedures ensure this dose-to-dose consistency — which is pharmacologically critical for both Mefenamic Acid (where under-dosing reduces efficacy) and Paracetamol (where accurate dosing is essential for safety).

• pH and Stability Management: The suspension vehicle must remain chemically stable for 24 months under tropical storage conditions. Our formulation team selects preservatives, pH buffers, and suspending agents that protect both actives from chemical degradation.

• Rapid Pain and Fever Relief: Both Mefenamic Acid and Paracetamol are well absorbed from the gastrointestinal tract, with Tmax typically achieved within 1–2 hours. This fast onset creates a clear, visible clinical outcome that both patients and prescribers notice quickly, building prescription loyalty and brand trust.

• Seasonal Repeat Demand: Analgesic and antipyretic suspensions are among the highest-frequency repurchase pharmaceutical products in the Indian market. A well-positioned brand in this category generates consistent prescription cycles through all seasons — particularly during monsoon and winter infection peaks.

• 60ml Price-to-Value Pack: The 60ml format is ideal for analgesic products because it typically covers a 5–7 day treatment course at standard dosing — matching the natural duration of most pain and fever episodes.

Saar Biotech provides Third-Party Manufacturing and Contract Manufacturing for Mefenamic Acid + Paracetamol Suspension from our dedicated oral suspension manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Oral liquid and suspension manufacturing area with controlled processing, automated bottle filling, capping, labelling, and carton packing lines suited for 60ml and 100ml presentations.
• Capacity: Scalable from brand-entry launches to large seasonal batches; 160×60ml, 100×100ml distributor dispatch configurations available.
• Quality Lab: In-house GLP-certified lab with validated HPLC assay for both actives, plus pH, viscosity, suspension uniformity, MLT, and fill volume checks.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 60ml and 100ml PET or dark amber bottles; sticker label, metallic label, silver leafing, drip-off carton, brand embossed carton, measuring cup, printed cap, with-carton or without-carton supply.
• MOQ: Starting at 5,000–10,000 units per SKU.

1. Warehouse Conditions: Store below 30°C in a cool, dry environment. Do not freeze — sub-zero temperatures will disrupt the suspension matrix and cause irreversible caking at the base of the bottle.
2. Shake Well Before Every Dose: This is the single most important user instruction for a suspension product. Proper shaking ensures the Mefenamic Acid is uniformly redispersed.
3. Measuring Cup Use: A calibrated measuring cup must accompany the bottle. Household spoons are unreliable for accurate dosing.
4. Light Protection: Dark amber bottles and outer cartons protect the suspension from light-induced degradation.

Every commercial batch of Mefenamic Acid + Paracetamol Suspension is quarantined until it passes a comprehensive analytical release protocol:

• Two-API HPLC Assay: Simultaneous quantification of Mefenamic Acid 100mg and Paracetamol 250mg per 5ml against IP specifications.
• Suspension Uniformity & Re-Dispersibility: Sediment behaviour and post-shaking uniformity are evaluated to ensure dose-to-dose consistency.
• pH & Viscosity Testing: The suspension vehicle’s pH and flow characteristics are monitored to maintain stability.
• Microbial Limit Testing (MLT): IP-compliant microbiological testing confirming absence of specified pathogens.
• Fill Volume & Pack Inspection: Automated fill-volume checks, cap torque, measuring-cup inclusion, label placement, and carton accuracy are verified before dispatch.
• Certificate of Analysis (COA): Issued with every B2B batch.

• Gastrointestinal Risk (Mefenamic Acid): Mefenamic Acid can cause gastrointestinal irritation, ulceration, and bleeding — particularly with prolonged use. Patients should take the suspension with or after food.
• Hepatotoxicity Risk (Paracetamol): The primary critical safety parameter. Severe hepatic necrosis can occur with overdose due to accumulation of the toxic NAPQI metabolite. Strict adherence to weight-based dosing (maximum 60 mg/kg/day for Paracetamol) is mandatory. Concurrent use of other paracetamol-containing products must be strictly avoided.
• Renal Precautions: Mefenamic Acid can cause fluid retention and renal toxicity in susceptible patients. Use with caution in patients with renal impairment.
• Contraindications: Active peptic ulcer disease, severe hepatic impairment, severe renal impairment, NSAID-induced asthma, and hypersensitivity to any component.

For third-party manufacturing enquiries, private-label contracts, or to request pricing and packaging options for Mefenamic Acid + Paracetamol Suspension, please use the B2B enquiry form below.